Barclays raised the firm’s price target on Novo Nordisk to DKK 1,050 from DKK 900 and keeps an Overweight rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NVO:
- Novo Nordisk’s (NYSE:NVO) Wegovy Set to Storm China’s Weight Loss Market
- Major Stocks Scale New Highs as Indices Set New Records
- Novo Nordisk (NYSE:NVO) Blasts Up on Weight Loss Drug News
- Unusually active option classes on open March 7th
- Novo Nordisk rallies after amycretin shows 13% weight loss in 12 weeks
